Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28259387 | 0.94 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL1994865 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL1994862 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL8261408 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL5593739 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL6656395 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL6656396 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL5967532 | 0.80 | L3MBTL1 (0.50) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL6672953 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB | |
| SCHEMBL10834757 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAL3MBTL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171885-A1 | Process for Preparation of Highly Pure Trandolapril | LUPIN LIMITED (IN) | 2008-07-17 | — | — | US | claimed |
| EP-1866327-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | Lupin Ltd. (IN) | 2007-12-19 | — | — | EP | claimed |
| WO-2006085332-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | LUPIN LIMITED (IN) | 2006-08-17 | — | — | WO | claimed |
| EP-0967221-A1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORPORATION (JP) | 1999-12-29 | — | — | EP | claimed |
| US-5359086-A | Process for preparing alkyl-L-alanyl-L-proline derivatives | KRKA, PHARMACEUTICAL & CHEMICAL WORKS (SI) | 1994-10-25 | — | — | US | claimed |
| US-20080171885-A1 | Process for Preparation of Highly Pure Trandolapril | LUPIN LIMITED (IN) | 2008-07-17 | — | — | US | disclosed |
| EP-1866327-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | Lupin Ltd. (IN) | 2007-12-19 | — | — | EP | disclosed |
| US-20070093664-A1 | Process for the production of lisinopril | ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) | 2007-04-26 | — | — | US | disclosed |
| WO-2006085332-A1 | IMPROVED PROCESS FOR PREPARATION OF HIGHLY PURE TRANDOLAPRIL | LUPIN LIMITED (IN) | 2006-08-17 | — | — | WO | disclosed |
| EP-1513868-B1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL (TR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1513868-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000874-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) | 2003-12-31 | — | — | WO | disclosed |
| EP-0967221-A1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORPORATION (JP) | 1999-12-29 | — | — | EP | disclosed |
| US-5359086-A | Process for preparing alkyl-L-alanyl-L-proline derivatives | KRKA, PHARMACEUTICAL & CHEMICAL WORKS (SI) | 1994-10-25 | — | — | US | disclosed |
| US-5359086-A | Process for preparing alkyl-L-alanyl-L-proline derivatives | KRKA, PHARMACEUTICAL & CHEMICAL WORKS (SI) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ACE, LOX, AGT | SMN1; SMN2 2164/4885LMNA 222/4885L3MBTL1 114/4885 |
| US-20080171885-A1 | Process for Preparation of Highly Pure Trandolapril | TPH1, HTR1A, HTR3A | SMN1; SMN2 3548/4885LMNA 693/4885L3MBTL1 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.